Altitude sickness (Acute Mountain Sickness — AMS) is the most common reason for Kilimanjaro summit failures — not fitness, not weather, not equipment. The summit failure rate on Kilimanjaro’s shortest route (Marangu/Coca Cola route, 5 days) is estimated at 60–70%; the success rate on the longer acclimatisation routes (Lemosho 8 days, Northern Circuit 9 days) is 85–90%. The single most important factor determining summit success on Kilimanjaro is not physical fitness but acclimatisation time — the time the body has to adjust to progressively reduced oxygen at altitude. Understanding the acclimatisation physiology, the AMS warning signs at each camp, and the correct response to symptoms is the most important pre-climb preparation any Kilimanjaro trekker can do. This guide covers altitude management for 2025 Kilimanjaro climbers.
Altitude and Acclimatisation Physiology
At 5,895 m (Uhuru Peak), the atmospheric pressure is approximately 52% of sea level — meaning each breath delivers approximately 52% of the oxygen available at sea level. The body’s adaptation to this reduced oxygen (acclimatisation): increased red blood cell production (taking 2–4 weeks for full adaptation), increased breathing rate, and changes to blood alkalinity. The Kilimanjaro ascent schedule (3–9 days depending on route) provides insufficient time for full physiological acclimatisation — the summit push relies on the body’s initial compensatory responses. The acclimatisation rule: most trekkers can ascend 300–500 m per day (sleeping altitude) without significant AMS symptoms. Kilimanjaro’s camp schedule on the short routes (Marangu 5-day) requires sleeping altitude increases of 700–900 m per day — far exceeding the safe acclimatisation rate and accounting for the high failure rate.
AMS Symptoms at Each Camp
Camp-by-camp AMS risk: Machame/Shira Camp 1 (2,835 m): mild headache, nausea — common and normal, almost always self-resolving overnight with hydration. Barranco Camp (3,950 m): significant headache, poor sleep, loss of appetite — the majority of climbers experience moderate symptoms at this altitude. The “Lava Tower day” (ascending to 4,600 m before descending to Barranco at 3,950 m) is the most important acclimatisation feature of the Machame route — spending 2 hours at 4,600 m before sleeping at 3,950 m (“walk high, sleep low”) dramatically reduces AMS incidence on the following days. Barafu Camp (4,673 m — summit night departure point): many trekkers feel worst here. Rest, hydration, and Diamox (if prescribed) management. Summit push (5,895 m): 20–30% of Kilimanjaro climbers who reach Barafu Camp experience severe AMS symptoms on the summit push — the most severe form (HACE — High Altitude Cerebral Oedema) requires immediate descent and is a medical emergency.
Diamox and Prevention
Acetazolamide (Diamox — brand name, generic available): a carbonic anhydrase inhibitor that accelerates acclimatisation by stimulating increased breathing rate (eliminating the blood alkalinity that inhibits breathing at altitude). The evidence for Diamox effectiveness on Kilimanjaro: consistent positive data — trekkers taking Diamox have lower AMS rates and higher summit success rates on all route lengths. Standard prescription: 125–250 mg twice daily, starting 24–48 hours before ascending above 3,000 m. Side effects: increased urination (carry adequate water — dehydration on Diamox is a real risk), tingling in hands and feet (paraesthesia — harmless and common), carbonated drinks tasting flat. Contraindication: sulfa drug allergy (Diamox is a sulfonamide derivative — do not take if sulfa allergy is known). Obtain a Diamox prescription before departure — most Kilimanjaro operators recommend consulting a travel medicine physician 4–6 weeks before the climb date.
